Article

PDF
Access to the PDF text
Advertising


Free Article !

Archives of cardiovascular diseases
Volume 102, n° S1
page 36 (mars 2009)
Doi : 10.1016/S1875-2136(09)72211-9
Themes et posters

D001 Prokineticin receptor signaling in cardiovascular function: foes or friends ?
 

C. Nebigil-desaubry
CNRS-Université Strasbourg, Strasbourg-Illkirch, France 

D — Angiogenese, facteurs de croissance, cellules progenitrices

@@#100979@@

Prokineticins are secreted peptides that activate two receptors. We investigated the role of each receptor in heart by generating transgenic (TG) mice overexpressing PKR1 or PKR2 in cardiomyocytes. TG-PKR1 displayed an increased number of epicardial-derived progenitor cells (EPDCs), capillary density and vessels, without inducing any cardiomyocyte abnormalities. Coculturing EPDCs with H9c2 cardiomyoblasts overexpressing PKR1 upragulates prokineticin-2 as a paracrine factor that promotes EPDC differentiation into endothelial and smooth muscle cells, mimicking our transgenic model. Exogenous prokineticin-2 induces neonatal and adult EPDC differentiation. These prokineticin-2 effects were abolished in EPDCs from mice with PKR1-null mutation, indicating involvement of PKR1. This study provides a novel insight for possible therapeutic strategies aiming at restoring pluripotency of adult EPDCs to promote neovasculogenesis by induction of cardiomyocyte PKR1 signaling. TG-PKR2 exhibit increased hypertrophic gene expressions and increased left ventricular endsystolic and diastolic diameters without cardiac dysfunction at the age of 24 weeks. TG hearts exhibit abnormal endothelial cell shape and ultrastructure, changed cellular distribution of a tight junction protein ZO-1, and vascular leakage in heart. The application of media conditioned by H9c2 cardioblast cells overexpressing PKR2 disturbed ZO-1 localization in H5V endothelial cells, mimicking the TG model. These findings showed that cardiomyocyte PKR2 signalling leads to eccentric hypertrophy in an autocrine regulation and impaired endothelial integrity in a paracrine regulation.

Our findings should facilitate the discovery of specific agonist and antagonist targeting PKR1 and PKR2 for possible use of treatment of ischemic heart diseases.

The full text of this article is available in PDF format.
The full text of this article is available in PDF format.
Click here to see it.

Top of the page

© 2009  Elsevier Masson SAS. All Rights Reserved.
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline
You can move this window by clicking on the headline
@@#110903@@